This year, the Society for Neuro-Oncology recognizes UCSF researchers Aaron Diaz, PhD and Radhika Mathur, PhD with awards at their annual meeting.
Campus News, Research
Published by Hear the Rare: Voices of the DIPG Community
Patient Care
Published today in Nature Communications, Raleigh and colleagues characterize the range of intratumor heterogeneity found in meningioma, identifying potential therapeutic targets.
Research
Published by UCSF Neurosurgery
Patient Care
This summer, the UCSF Brain Tumor Center launched a newly renovated support program for family caregivers of patients with brain tumors.
Campus News, Caregiver News
Published by Precision Oncology News
Patient Care, Research
Published by UCSF News
Campus News, Patient Care
This month, neuro-oncologist Jessica Schulte, MD, PhD joins the UCSF Brain Tumor Center team. Dr. Schulte specializes in treatment of adolescent and adult glioma and neurofibromatosis.
Campus News, Patient Care
Published by UCSF News
Campus News, Patient Care
Mary Destri joins the UCSF Neuro-Oncology team as the programming liaison to extend Neuro-Oncology supportive care services and resources to our patients and families in the North Bay.
Campus News, Caregiver News, Patient Care
Comprehensive analysis of a rare tumor type identifies pediatric bithalamic glioma as a distinct tumor entity with potential sensitivity to a genomically-guided treatment strategy.
Research
Researchers at UC San Francisco have discovered how PGAM1 – a protein expressed at high levels in many cancers – can contribute to tumor cells’ resistance to radiation therapy and chemotherapy.
Research
Published by UCSF Neurosurgery
Patient Care
Hosted by long-time supporters Alan and Ashley Dabbiere, the event also paid tribute to the pioneering work of the Center’s director, Mitchel Berger, MD.
Campus News, Patient Care
Published by i3 Health News & Perspectives
Patient Care, Research
Within the next few months, the UCSF Brain Tumor Center will begin recruiting for a multi-center clinical trial to evaluate AG-881 for treatment of recurrent IDH-mutant grade II glioma.
Research